

**Clinical trial results:****A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Long-Term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors****Summary**

EudraCT number	2013-000324-34
Trial protocol	PL
Global end of trial date	14 May 2018

Results information

Result version number	v2 (current)
This version publication date	13 July 2019
First version publication date	30 May 2019
Version creation reason	• Changes to summary attachments Updates to be made in the time frame of 2 endpoints and 1 analysis population description.

Trial information**Trial identification**

Sponsor protocol code	APD356-G000-401
-----------------------	-----------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02019264
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Eisai Ltd.
Sponsor organisation address	European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, United Kingdom, AL10 9SN
Public contact	Eisai Medical Information, Eisai Ltd., +1 888-274-2378, esi_medinfo@eisai.com
Scientific contact	Eisai Medical Information, Eisai Ltd., +1 888-274-2378, esi_medinfo@eisai.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	14 May 2018
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	14 May 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To demonstrate that, in obese and overweight subjects with cardiovascular (CV) disease and/or multiple CV risk factors, lorcaserin hydrochloride (HCl) 10 milligram (mg) administered twice daily (BID) does not increase the incidence of major adverse cardiovascular events (MACE) (myocardial infarction [MI], or stroke, or CV death) compared to placebo, with a noninferiority margin for the hazard ratio (HR) of 1.4, and in obese and overweight subjects with CV disease and/or multiple CV risk factors, lorcaserin HCl 10 mg BID reduces the incidence of MACE+ (MACE or hospitalization for unstable angina or heart failure [HF], or any coronary revascularization) compared to placebo

Protection of trial subjects:

This study was conducted in accordance with standard operating procedures (SOPs) of the sponsor (or designee), which are designed to ensure adherence to Good Clinical Practice (GCP) guidelines as required by the following:

- Principles of the World Medical Association Declaration of Helsinki (World Medical Association, 2008)
- International Council on Harmonisation (ICH) E6 Guideline for GCP (CPMP/ICH/135/95) of the European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products, International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
- Title 21 of the United States (US) Code of Federal Regulations (US 21 CFR) regarding clinical studies, including Part 50 and Part 56 concerning informed subject consent and Institutional Review Board (IRB) regulations and applicable sections of US 21 CFR Part 312
- European Good Clinical Practice Directive 2005/28/EC and Clinical Trial Directive 2001/20/EC for studies conducted within any European Union (EU) country. All suspected unexpected serious adverse reactions were reported, as required, to the Competent Authorities of all involved EU member states.
- Article 14, Paragraph 3, and Article 80-2 of the Pharmaceutical Affairs Law (Law No. 145, 1960) for studies conducted in Japan, in addition to Japan's GCP Subject Information and Informed Consent.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	24 January 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 535
Country: Number of subjects enrolled	Bahamas: 10
Country: Number of subjects enrolled	Canada: 1165
Country: Number of subjects enrolled	Chile: 107

Country: Number of subjects enrolled	Mexico: 255
Country: Number of subjects enrolled	New Zealand: 316
Country: Number of subjects enrolled	Poland: 985
Country: Number of subjects enrolled	United States: 8627
Worldwide total number of subjects	12000
EEA total number of subjects	985

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	6257
From 65 to 84 years	5699
85 years and over	44

Subject disposition

Recruitment

Recruitment details:

Subjects took part in the study at investigative sites in the United States, Bahamas, Canada, Mexico, Chile, New Zealand, Poland, and Australia from 24 Jan 2014 to 14 May 2018.

Pre-assignment

Screening details:

A total of 14,673 subjects were screened and enrolled, of which 2673 subjects were screen failures and 12,000 were randomized to receive lorcaserin HCl or placebo.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Subjects received lorcaserin HCL placebo-matching, tablets, orally, twice daily for up to 52 months.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Lorcaserin HCL placebo-matching, tablets, orally, twice daily for up to 52 months.

Arm title	Lorcaserin 10 mg
------------------	------------------

Arm description:

Subjects received lorcaserin HCL 10 mg, tablets, orally, twice daily for up to 52 months.

Arm type	Experimental
Investigational medicinal product name	Lorcaserin
Investigational medicinal product code	
Other name	APD356, BELVIQ
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Lorcaserin HCL 10 mg, tablets, orally, twice daily for up to 52 months.

Number of subjects in period 1	Placebo	Lorcaserin 10 mg
Started	6000	6000
Completed	5752	5793
Not completed	248	207
Not Treated	6	4
Withdrawal by subjects	142	117
Lost to follow-up	50	47
Missing	14	11
Administrative reason	36	28

Baseline characteristics

Reporting groups

Reporting group title	Placebo
Reporting group description:	
Subjects received lorcaserin HCL placebo-matching, tablets, orally, twice daily for up to 52 months.	
Reporting group title	Lorcaserin 10 mg
Reporting group description:	
Subjects received lorcaserin HCL 10 mg, tablets, orally, twice daily for up to 52 months.	

Reporting group values	Placebo	Lorcaserin 10 mg	Total
Number of subjects	6000	6000	12000
Age categorical			
Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous			
Units: years			
arithmetic mean	63.7	63.5	
standard deviation	± 8.31	± 8.33	-
Gender categorical			
Units: Subjects			
Female	2186	2112	4298
Male	3814	3888	7702
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	536	502	1038
Not Hispanic or Latino	5464	5498	10962
Unknown or Not Reported	0	0	0
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	21	26	47
Asian	74	85	159
Native Hawaiian or Other Pacific Islander	23	30	53
Black or African American	466	454	920
White	5331	5309	10640
More than one race	85	96	181
Unknown or Not Reported	0	0	0

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description:	
Subjects received lorcaserin HCL placebo-matching, tablets, orally, twice daily for up to 52 months.	
Reporting group title	Lorcaserin 10 mg
Reporting group description:	
Subjects received lorcaserin HCL 10 mg, tablets, orally, twice daily for up to 52 months.	

Primary: Time From Randomization to First Occurrence of Major Adverse Cardiovascular Events (MACE) at Interim Analysis

End point title	Time From Randomization to First Occurrence of Major Adverse Cardiovascular Events (MACE) at Interim Analysis
End point description:	
The MACE events involved MI, stroke, or CV death. The outcome data was assessed using Kaplan-Meier estimate and Greenwood Formula. The total time analysis set using the intent-to-treat (ITT) set, events were counted that occurred while subjects were on and off treatment. Subjects with no events were censored at their last study contact or at the visit following sponsor notification of study completion, whichever occurred first. Here "99999" refers to median time and 95% confidence interval which could not be calculated since quartile was not estimable due to higher number of censored subjects.	
End point type	Primary
End point timeframe:	
Baseline up to Month 42	

End point values	Placebo	Lorcaserin 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6000	6000		
Units: days				
median (confidence interval 95%)	99999 (99999 to 99999)	99999 (99999 to 99999)		

Statistical analyses

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Placebo v Lorcaserin 10 mg
Number of subjects included in analysis	12000
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[1]
P-value	< 0.0001
Method	Primary Analytic Method
Parameter estimate	Hazard ratio (HR)
Point estimate	1.005

Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.842
upper limit	1.198

Notes:

[1] - Hazard ratio was based on Cox-regression model including treatment and CV strata as covariates. MACE met non-inferiority when the one-sided upper bound of 97.5% confidence interval of the HR was less than (<) 1.4 (the non-inferiority margin).

Primary: Time From Randomization to First Occurrence of MACE+

End point title	Time From Randomization to First Occurrence of MACE+
End point description:	
The MACE+ events involved MI, stroke, or CV death or hospitalization for unstable angina or heart failure (HF), or any coronary revascularization. The outcome data was assessed using Kaplan-Meier estimate and Greenwood Formula. The total time analysis set used the ITT set, events were counted that occurred while subjects were on and off treatment. Subjects with no events were censored at their last study contact or at the visit following Sponsor Notification of Study Completion, whichever occurred first. Here "99999" refers to median time and 95% confidence interval which could not be calculated since quartile was not estimable due to higher number of censored subjects.	
End point type	Primary
End point timeframe:	
Baseline up to end of study (Month 56)	

End point values	Placebo	Lorcaserin 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6000	6000		
Units: days				
median (confidence interval 95%)	99999 (99999 to 99999)	99999 (99999 to 99999)		

Statistical analyses

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Placebo v Lorcaserin 10 mg
Number of subjects included in analysis	12000
Analysis specification	Pre-specified
Analysis type	superiority ^[2]
P-value	= 0.5464
Method	Primary Analytic Method
Parameter estimate	Hazard ratio (HR)
Point estimate	0.969
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.873
upper limit	1.074

Notes:

[2] - Hazard ratio was based on Cox-regression model including treatment and CV strata as covariates.

Secondary: Time From Randomization to Conversion to Type 2 Diabetes Mellitus (T2DM) for Subjects With Prediabetes at Baseline

End point title	Time From Randomization to Conversion to Type 2 Diabetes Mellitus (T2DM) for Subjects With Prediabetes at Baseline
-----------------	--

End point description:

Time from randomization to conversion to T2DM was defined as first occurrence of any component of the 2013 American Diabetes Association (ADA) Diagnostic Criteria (ADA, 2013) in subjects with prediabetes at baseline. The outcome data was assessed using Kaplan-Meier estimate and Greenwood Formula.

Prediabetes and total time analysis set used ITT set: without a history of any type of diabetes and who were prediabetic at baseline; events were counted that occurred while subjects were on, off treatment; subjects with no events were censored at last study contact/at visit after notification of study completion, whichever occurred first. Here "99999" refers to median time and 95% confidence interval which could not be calculated since quartile was not estimable due to higher number of censored subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to end of study (Month 56)

End point values	Placebo	Lorcaserin 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1976	2015		
Units: days				
median (confidence interval 95%)	99999 (99999 to 99999)	99999 (99999 to 99999)		

Statistical analyses

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Placebo v Lorcaserin 10 mg
Number of subjects included in analysis	3991
Analysis specification	Pre-specified
Analysis type	superiority ^[3]
P-value	= 0.038
Method	Primary Analytic Method
Parameter estimate	Hazard ratio (HR)
Point estimate	0.807
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.659
upper limit	0.988

Notes:

[3] - Hazard ratio was based on Cox-regression model including treatment as covariate.

Secondary: Time From Randomization to First Occurrence of the Individual Components of MACE+

End point title	Time From Randomization to First Occurrence of the Individual Components of MACE+
-----------------	---

End point description:

The MACE+ events involved MI, stroke, or CV death or hospitalization for unstable angina or HF, or any coronary revascularization. The outcome data was assessed using Kaplan-Meier estimate and Greenwood Formula. The total time analysis set used the ITT set, events counted occurred while subjects were on and off treatment. Subjects with no events were censored at last study contact or at the visit following Sponsor Notification of Study Completion, whichever first. Here "99999" refers to median time and 95% confidence interval which could not be calculated since quartile was not estimable due to higher number of censored subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to end of study (Month 56)

End point values	Placebo	Lorcaserin 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6000	6000		
Units: days				
arithmetic mean (confidence interval 95%)				
MI	99999 (99999 to 99999)	99999 (99999 to 99999)		
Stroke	99999 (99999 to 99999)	99999 (99999 to 99999)		
CV death	99999 (99999 to 99999)	99999 (99999 to 99999)		
Hospitalization for unstable angina	99999 (99999 to 99999)	99999 (99999 to 99999)		
HF	99999 (99999 to 99999)	99999 (99999 to 99999)		
Coronary revascularization	99999 (99999 to 99999)	99999 (99999 to 99999)		

Statistical analyses

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Placebo v Lorcaserin 10 mg
Number of subjects included in analysis	12000
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[4]
P-value	= 0.0001
Method	Primary Analytic Method
Parameter estimate	Hazard ratio (HR)
Point estimate	0.991

Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.824
upper limit	1.191

Notes:

[4] - MI: Hazard ratio was based on Cox-regression model including treatment and CV strata as covariates. 97.5% confidence interval refers to the upper limit of the displayed 2-sided 95% confidence interval.

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Placebo v Lorcaserin 10 mg
Number of subjects included in analysis	12000
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[5]
P-value	= 0.0005
Method	Primary Analytic Method
Parameter estimate	Hazard ratio (HR)
Point estimate	0.856
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.639
upper limit	1.145

Notes:

[5] - Time to Stroke: Hazard ratio was based on Cox-regression model including treatment and CV strata as covariates. 97.5% confidence interval refers to the upper limit of the displayed 2-sided 95% confidence interval.

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Placebo v Lorcaserin 10 mg
Number of subjects included in analysis	12000
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[6]
P-value	= 0.0262
Method	Primary Analytic Method
Parameter estimate	Hazard ratio (HR)
Point estimate	1.045
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.778
upper limit	1.404

Notes:

[6] - Cardiovascular Death: Hazard ratio was based on Cox-regression model including treatment and CV strata as covariates. 97.5% confidence interval refers to the upper limit of the displayed 2-sided 95% confidence interval.

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Placebo v Lorcaserin 10 mg

Number of subjects included in analysis	12000
Analysis specification	Pre-specified
Analysis type	superiority ^[7]
P-value	= 0.3243
Method	Primary Analytic Method
Parameter estimate	Hazard ratio (HR)
Point estimate	1.163
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.861
upper limit	1.571

Notes:

[7] - Hospitalization for Unstable Angina: Hazard ratio was based on Cox-regression model including treatment and CV strata as covariates.

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Placebo v Lorcaserin 10 mg
Number of subjects included in analysis	12000
Analysis specification	Pre-specified
Analysis type	superiority ^[8]
P-value	= 0.6758
Method	Primary Analytic Method
Parameter estimate	Hazard ratio (HR)
Point estimate	0.952
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.757
upper limit	1.197

Notes:

[8] - HF: Hazard ratio was based on Cox-regression model including treatment and CV strata as covariates.

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Placebo v Lorcaserin 10 mg
Number of subjects included in analysis	12000
Analysis specification	Pre-specified
Analysis type	superiority ^[9]
P-value	= 0.7817
Method	Primary Analytic Method
Parameter estimate	Hazard ratio (HR)
Point estimate	0.981
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.856
upper limit	1.125

Notes:

[9] - Coronary Revascularization: Hazard ratio was based on Cox-regression model including treatment and CV strata as covariates.

Secondary: Time From Randomization to Event of All-cause Mortality

End point title	Time From Randomization to Event of All-cause Mortality
End point description:	
The outcome data was assessed using Kaplan-Meier estimate and Greenwood Formula. The total time analysis set used the ITT set, events were counted that occurred while subjects were on and off treatment. Subjects with no events were censored at their last study contact or at the visit following Sponsor Notification of Study Completion, whichever occurred first. Here "99999" refers to median time and 95% confidence interval which could not be calculated since quartile was not estimable due to higher number of censored subjects.	
End point type	Secondary
End point timeframe:	
Baseline up to end of study (Month 56)	

End point values	Placebo	Lorcaserin 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6000	6000		
Units: days				
median (confidence interval 95%)	99999 (99999 to 99999)	99999 (99999 to 99999)		

Statistical analyses

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Placebo v Lorcaserin 10 mg
Number of subjects included in analysis	12000
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4212
Method	Primary Analytic Method
Parameter estimate	Hazard ratio (HR)
Point estimate	1.082
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.893
upper limit	1.31

Secondary: Time From Randomization to Conversion to Normal Glucose Homeostasis in Subjects With Prediabetes at Baseline

End point title	Time From Randomization to Conversion to Normal Glucose Homeostasis in Subjects With Prediabetes at Baseline
End point description:	
Normal glucose homeostasis was defined as glycosylated hemoglobin (HbA1c) less than or equal to (\leq) 5.6% and fasting plasma glucose (FPG) < 100 milligram per deciliter (mg/dL) without any antidiabetic treatment. The outcome data was assessed using Kaplan-Meier estimate and Greenwood Formula. The prediabetes analysis set included all subjects in the ITT set without a history of any type of diabetes and who were prediabetic at baseline. Here "99999" refers to median time and 95% confidence interval which could not be calculated since quartile was not estimable due to higher number of	

censored subjects.

End point type	Secondary
End point timeframe:	
Baseline up to end of study (Month 56)	

End point values	Placebo	Lorcaserin 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1976	2015		
Units: days				
median (confidence interval 95%)	99999 (99999 to 99999)	99999 (99999 to 99999)		

Statistical analyses

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Placebo v Lorcaserin 10 mg
Number of subjects included in analysis	3991
Analysis specification	Pre-specified
Analysis type	superiority ^[10]
P-value	= 0.181
Method	Primary Analytic Method
Parameter estimate	Hazard ratio (HR)
Point estimate	1.124
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.947
upper limit	1.333

Notes:

[10] - Hazard ratio was based on a Cox regression model including treatment as covariate.

Secondary: Time From Randomization to Conversion to T2DM for Subjects Without Any Type of Diabetes at Baseline

End point title	Time From Randomization to Conversion to T2DM for Subjects Without Any Type of Diabetes at Baseline
End point description:	
The outcome data was assessed using Kaplan-Meier estimate and Greenwood Formula. The nondiabetes analysis set included all subjects in the ITT set without a history of any type of diabetes at baseline. Here "99999" refers to median time and 95% confidence interval which could not be calculated since quartile was not estimable due to higher number of censored subjects.	
End point type	Secondary
End point timeframe:	
Baseline up to end of study (Month 56)	

End point values	Placebo	Lorcaserin 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2569	2615		
Units: days				
median (confidence interval 95%)	99999 (99999 to 99999)	99999 (99999 to 99999)		

Statistical analyses

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Placebo v Lorcaserin 10 mg
Number of subjects included in analysis	5184
Analysis specification	Pre-specified
Analysis type	superiority ^[11]
P-value	= 0.0116
Method	Primary Analytic Method
Parameter estimate	Hazard ratio (HR)
Point estimate	0.773
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.633
upper limit	0.944

Notes:

[11] - Hazard ratio was based on a Cox regression model including treatment as covariate.

Secondary: Change From Baseline in HbA1c at Month 6 in Subjects With T2DM at Baseline

End point title	Change From Baseline in HbA1c at Month 6 in Subjects With T2DM at Baseline
End point description:	The T2DM analysis set included all subjects in the ITT set who had T2DM at baseline. Here "n" was the T2DM analysis set where data was available at specified time points.
End point type	Secondary
End point timeframe:	Baseline, and Month 6

End point values	Placebo	Lorcaserin 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3403	3362		
Units: percentage of HbA1c				
arithmetic mean (standard deviation)				
Baseline (n=3403, 3362)	6.99 (± 1.066)	7.01 (± 1.082)		
Change at Month 6 (n=3087, 3035)	0.06 (± 0.777)	-0.33 (± 0.785)		

Statistical analyses

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Placebo v Lorcaserin 10 mg
Number of subjects included in analysis	6765
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[12]
Method	ANCOVA
Parameter estimate	Least square (LS) Mean Difference (Net)
Point estimate	-0.39
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.43
upper limit	-0.35

Notes:

[12] - P-value was based on analysis of covariance (ANCOVA) model with treatment and stratification variable (presence of established CV disease or CV risk factors without established CV disease) as factors, and baseline HbA1c, as a covariate.

Secondary: Time From Randomization to Event of New Onset Renal Impairment or Worsening Existing Renal Impairment in All Subjects

End point title	Time From Randomization to Event of New Onset Renal Impairment or Worsening Existing Renal Impairment in All Subjects
-----------------	---

End point description:

New onset/worsening of existing renal impairment was first occurrence of any events: microalbuminuria and macroalbuminuria, worsening albuminuria (microalbuminuria at Baseline developed macroalbuminuria, ACR increased $\geq 30\%$ from Baseline during treatment), newly developed chronic kidney disease (CKD) or worsening of CKD (based on National Kidney Foundation [NKF] Guidelines [2002]) worsened to higher CKD stages during treatment), or doubling of serum creatinine (creatinine value at least 2 times Baseline value and ≥ 1.5 mg/dL during treatment.), or any of following: end-stage renal disease, renal transplant, renal death. Outcome data was assessed using Kaplan-Meier estimate and Greenwood Formula. ITT set included all randomized subjects regardless of whether they took study drug or not. This set was the same as full analysis set. "99999": Median time and 95% confidence interval which could not be calculated since quartile was not estimable due to higher number of censored subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to end of study (Month 56)

End point values	Placebo	Lorcaserin 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6000	6000		
Units: days				
median (confidence interval 95%)	99999 (99999 to 99999)	99999 (99999 to 99999)		

Statistical analyses

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Placebo v Lorcaserin 10 mg
Number of subjects included in analysis	12000
Analysis specification	Pre-specified
Analysis type	superiority ^[13]
P-value	= 0.0054
Method	Primary Analytic Method
Parameter estimate	Hazard ratio (HR)
Point estimate	0.869
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.787
upper limit	0.959

Notes:

[13] - Hazard ratio was based on Cox-regression model including treatment and CV strata as covariates.

Secondary: Time From Randomization to Event of New Onset Renal Impairment or Worsening Existing Renal Impairment in Subjects With Prediabetes at Baseline

End point title	Time From Randomization to Event of New Onset Renal Impairment or Worsening Existing Renal Impairment in Subjects With Prediabetes at Baseline
-----------------	--

End point description:

New onset/worsening of existing renal impairment was first occurrence of any events: microalbuminuria and macroalbuminuria, worsening albuminuria (microalbuminuria at Baseline developed macroalbuminuria, ACR increased $\geq 30\%$ from baseline during treatment), CKD as per NKF Guidelines [2002]) or worsening of CKD (CKD Stage1/higher as per NKF Guidelines [2002] worsened to higher CKD stages during treatment), or doubling serum creatinine(creatinine value at least twice baseline value and ≥ 1.5 mg/dL during treatment.), or any of: end stage renal disease, renal transplant, renal death. Outcome data was assessed using Kaplan-Meier estimate and Greenwood Formula. ITT set included all subjects without a history of any type of diabetes and were prediabetic at baseline. This set was the same as full analysis set. Here "99999" refers to median time and 95% confidence interval which could not be calculated since quartile was not estimable due to higher number of censored subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to end of study (Month 56)

End point values	Placebo	Lorcaserin 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1976	2015		
Units: days				
median (confidence interval 95%)	99999 (99999 to 99999)	99999 (99999 to 99999)		

Statistical analyses

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Placebo v Lorcaserin 10 mg
Number of subjects included in analysis	3991
Analysis specification	Pre-specified
Analysis type	superiority ^[14]
P-value	= 0.3661
Method	Primary Analytic Method
Parameter estimate	Hazard ratio (HR)
Point estimate	0.904
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.727
upper limit	1.125

Notes:

[14] - Hazard ratio on a Cox regression model including treatment as covariate.

Secondary: Time From Randomization to Event of New Onset Renal Impairment or Worsening Existing Renal Impairment in Subjects With T2DM at Baseline

End point title	Time From Randomization to Event of New Onset Renal Impairment or Worsening Existing Renal Impairment in Subjects With T2DM at Baseline
-----------------	---

End point description:

New onset/worsening of existing renal impairment was first occurrence of any events: microalbuminuria and macroalbuminuria, worsening albuminuria (microalbuminuria at baseline developed macroalbuminuria, ACR increased $\geq 30\%$ from baseline during treatment), CKD as per NKF Guidelines [2002]) or worsening of CKD (CKD Stage 1/higher as per NKF Guidelines [2002] worsened to higher CKD stages during treatment), or doubling of serum creatinine (creatinine value at least 2 times baseline value and ≥ 1.5 mg/dL during treatment.), or any of the following: end-stage renal disease, renal transplant, renal death. The outcome data was assessed using Kaplan-Meier estimate and Greenwood Formula. The T2DM analysis set had all subjects in the ITT set who had T2DM at baseline. Here "99999" refers to median time and 95% confidence interval which could not be calculated since quartile was not estimable due to higher number of censored subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to end of study (Month 56)

End point values	Placebo	Lorcaserin 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3403	3362		
Units: days				
median (confidence interval 95%)	99999 (99999 to 99999)	99999 (99999 to 99999)		

Statistical analyses

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Placebo v Lorcaserin 10 mg
Number of subjects included in analysis	6765
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0082
Method	Primary Analytic Method
Parameter estimate	Hazard ratio (HR)
Point estimate	0.855
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.762
upper limit	0.96

Secondary: Time From Randomization to Event of Improvement in Renal Function in Subjects With T2DM at Baseline

End point title	Time From Randomization to Event of Improvement in Renal Function in Subjects With T2DM at Baseline
End point description:	Improvement in renal function: first occurrence of regression of albuminuria/regression of CKD. Regression of albuminuria: when subjects with macroalbuminuria at baseline developed microalbuminuria or nonalbuminuria, or subjects with microalbuminuria at baseline became nonalbuminuric, and ACR value decreased $\geq 30\%$ from previous assessment in treatment. Regression of CKD: when subjects with CKD Stage 1/higher at baseline improved to normal/lower stages by NKF guidelines in treatment. The outcome data was assessed using Kaplan-Meier estimate and Greenwood Formula. The T2DM analysis set included all subjects in ITT set who had T2DM at baseline. Here "99999" refers to median time and 95% confidence interval which could not be calculated since quartile was not estimable due to higher number of censored subjects.
End point type	Secondary
End point timeframe:	
Baseline up to end of study (Month 56)	

End point values	Placebo	Lorcaserin 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3403	3362		
Units: days				
median (confidence interval 95%)	99999 (99999 to 99999)	99999 (99999 to 99999)		

Statistical analyses

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Placebo v Lorcaserin 10 mg
Number of subjects included in analysis	6765
Analysis specification	Pre-specified
Analysis type	superiority ^[15]
P-value	= 0.0297
Method	Primary Analytic Method
Parameter estimate	Hazard ratio (HR)
Point estimate	1.182
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.017
upper limit	1.375

Notes:

[15] - Hazard ratio was based on Cox-regression model including treatment and CV strata as covariates.

Secondary: Percentage of Subjects Who Met FDA-Defined Valvulopathy in Echocardiographically Determined Heart Valve Changes

End point title	Percentage of Subjects Who Met FDA-Defined Valvulopathy in Echocardiographically Determined Heart Valve Changes
End point description:	
The FDA-defined valvulopathy analysis set included all subjects in the ITT set without FDA-defined valvulopathy at baseline. Here "n" was the FDA-defined valvulopathy analysis set where data was available at specified time point.	
End point type	Secondary
End point timeframe:	
Months 6 and 12	

End point values	Placebo	Lorcaserin 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1935	1925		
Units: percentage of subjects				
number (not applicable)				
Month 6 (n=1683, 1681)	1.4	2.1		
Month 12 (n=1564, 1579)	1.5	1.8		

Statistical analyses

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Placebo v Lorcaserin 10 mg
Number of subjects included in analysis	3860
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5015 ^[16]
Method	Primary Analytic Method
Parameter estimate	Odds ratio (OR)
Point estimate	1.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.69
upper limit	2.11

Notes:

[16] - P-value was based on logistic regression including treatment as a factor and baseline body mass index (BMI) as a covariate.

Secondary: Percentage of Subjects With FDA-Defined Valvulopathy at Baseline Who Demonstrated Worsened FDA-Defined Valvulopathy

End point title	Percentage of Subjects With FDA-Defined Valvulopathy at Baseline Who Demonstrated Worsened FDA-Defined Valvulopathy
-----------------	---

End point description:

The ITT analysis set in subjects with FDA-defined valvulopathy at baseline was used. Here "n" was the ITT analysis set in subjects with FDA-defined valvulopathy at baseline where data was available at specified time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Months 6 and 12

End point values	Placebo	Lorcaserin 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	228	225		
Units: percentage of subjects				
number (not applicable)				
Month 6 (n=194, 201)	2.1	3.5		
Month 12 (n=180, 189)	1.7	2.1		

Statistical analyses

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Placebo v Lorcaserin 10 mg
Number of subjects included in analysis	453
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7249 ^[17]
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.29
upper limit	5.98

Notes:

[17] - P-value was based on logistic regression including treatment as a factor and baseline BMI as a covariate.

Secondary: Change From Baseline in Echocardiographically-Determined Pulmonary Arterial Systolic Pressure

End point title	Change From Baseline in Echocardiographically-Determined Pulmonary Arterial Systolic Pressure
-----------------	---

End point description:

The ITT analysis set-subjects in ECHO substudy included all randomized subjects regardless of whether they took study drug or not. Here "n" was the ITT analysis set-subjects in the ECHO substudy, where data was available at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 12

End point values	Placebo	Lorcaserin 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2167	2151		
Units: Millimeter of mercury (mmHg)				
arithmetic mean (standard deviation)				
Baseline (n=1368, 1358)	26.4354 (± 7.66312)	26.2029 (± 7.54123)		
Change at Month 12 (n=882, 893)	-0.6418 (± 6.81716)	-0.8223 (± 7.23770)		

Statistical analyses

Statistical analysis title	Placebo, Lorcaserin 10 mg
Comparison groups	Lorcaserin 10 mg v Placebo

Number of subjects included in analysis	4318
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2976 ^[18]
Method	Mixed-effects model
Parameter estimate	Mean difference (net)
Point estimate	-0.9036
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.2908
upper limit	-0.5163

Notes:

[18] - P value was based on a mixed-effects model (unstructured covariance matrix) with repeated measures with treatment, month and treatment by month interaction as factors and baseline pulmonary arterial systolic pressure and baseline BMI as covariates.

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From baseline up to 30 days after last dose of study drug (approximately 56 months)

Adverse event reporting additional description:

Adverse events were collected for the subject who were in the safety analysis set (all subjects who received at least 1 dose of study drug and had at least one post dose safety assessment).

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects received lorcaserin HCL placebo-matching, tablets, orally, twice daily for up to 52 months.

Reporting group title	Lorcaserin 10 mg
-----------------------	------------------

Reporting group description:

Subjects received lorcaserin HCL 10 mg, tablets, orally, twice daily for up to 52 months.

Serious adverse events	Placebo	Lorcaserin 10 mg	
Total subjects affected by serious adverse events			
subjects affected / exposed	2021 / 5992 (33.73%)	1974 / 5995 (32.93%)	
number of deaths (all causes)	202	219	
number of deaths resulting from adverse events	121	132	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute leukaemia			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myeloid leukaemia			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Adenocarcinoma gastric			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma of appendix			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Adenocarcinoma of colon			
subjects affected / exposed	4 / 5992 (0.07%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma pancreas			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 1	1 / 1	
Adrenal adenoma			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenal gland cancer			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenal neoplasm			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal squamous cell carcinoma			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiomyolipoma			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendix cancer			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Atypical fibroxanthoma			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
B-cell lymphoma			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
B-cell lymphoma stage III			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	4 / 5992 (0.07%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign gastric neoplasm			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of ampulla of Vater			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of bladder			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of thyroid gland			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign renal neoplasm			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign small intestinal neoplasm			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary neoplasm			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer			
subjects affected / exposed	5 / 5992 (0.08%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer recurrent			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neoplasm			
subjects affected / exposed	2 / 5992 (0.03%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma			

subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma recurrent			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone cancer			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone cancer metastatic			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain cancer metastatic			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Brain neoplasm			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer			
subjects affected / exposed	9 / 5992 (0.15%)	11 / 5995 (0.18%)	
occurrences causally related to treatment / all	0 / 9	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer in situ			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer metastatic			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervix carcinoma			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervix carcinoma stage IV			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cholangiocarcinoma			
subjects affected / exposed	1 / 5992 (0.02%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 2	
Choroid melanoma			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Choroid neoplasm			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic lymphocytic leukaemia			
subjects affected / exposed	3 / 5992 (0.05%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	1 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Chronic myeloid leukaemia			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clear cell renal cell carcinoma			

subjects affected / exposed	3 / 5992 (0.05%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	1 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon adenoma			
subjects affected / exposed	11 / 5992 (0.18%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	2 / 12	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer			
subjects affected / exposed	7 / 5992 (0.12%)	9 / 5995 (0.15%)	
occurrences causally related to treatment / all	0 / 7	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer metastatic			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon neoplasm			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal adenocarcinoma			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal cancer stage IV			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Diffuse large B-cell lymphoma			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Endometrial adenocarcinoma			

subjects affected / exposed	5 / 5992 (0.08%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial cancer			
subjects affected / exposed	7 / 5992 (0.12%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 7	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extranodal marginal zone B-cell lymphoma (MALT type)			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibroadenoma of breast			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibroma			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Follicular thyroid cancer			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric cancer			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric cancer stage 0			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal stromal tumour			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glioblastoma			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Glioblastoma multiforme			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Hepatic cancer			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Hepatic cancer metastatic			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hepatocellular carcinoma			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hodgkin's disease			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal adenocarcinoma			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intraductal papillary mucinous neoplasm			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intraductal papillary-mucinous carcinoma of pancreas			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intraductal papilloma of breast			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intraductal proliferative breast lesion			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Invasive breast carcinoma			
subjects affected / exposed	3 / 5992 (0.05%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Invasive ductal breast carcinoma			
subjects affected / exposed	8 / 5992 (0.13%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 9	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Keratoacanthoma			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kidney angiomyolipoma			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lipoma			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma			
subjects affected / exposed	3 / 5992 (0.05%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 1	
Lung adenocarcinoma stage 0			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma stage IV			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Lung cancer metastatic			
subjects affected / exposed	3 / 5992 (0.05%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Lung carcinoma cell type unspecified stage III			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm malignant			
subjects affected / exposed	6 / 5992 (0.10%)	13 / 5995 (0.22%)	
occurrences causally related to treatment / all	0 / 6	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 1	
Lung squamous cell carcinoma stage II			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoma			
subjects affected / exposed	4 / 5992 (0.07%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma			
subjects affected / exposed	17 / 5992 (0.28%)	20 / 5995 (0.33%)	
occurrences causally related to treatment / all	0 / 21	0 / 24	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma in situ			
subjects affected / exposed	3 / 5992 (0.05%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma stage I			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm of ampulla of Vater			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Malignant neoplasm of spinal cord			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm of unknown primary site			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Malignant sweat gland neoplasm			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melanocytic naevus			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma benign			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to bone			
subjects affected / exposed	6 / 5992 (0.10%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 6	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastases to liver			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Metastases to lung			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to lymph nodes			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastasis			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic carcinoma of the bladder			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastatic malignant melanoma			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastatic renal cell carcinoma			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic squamous cell carcinoma			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mucinous cystadenocarcinoma ovary			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Mycosis fungoides			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelodysplastic syndrome			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myxofibrosarcoma			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasopharyngeal cancer			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm prostate			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm skin			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine carcinoma metastatic			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine tumour			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nodular melanoma			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-Hodgkin's lymphoma			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-small cell lung cancer			

subjects affected / exposed	3 / 5992 (0.05%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 1	
Non-small cell lung cancer stage I			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal adenocarcinoma			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Oesophageal adenocarcinoma metastatic			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Oesophageal carcinoma			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Oropharyngeal cancer			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian adenoma			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cancer metastatic			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pancreatic carcinoma			

subjects affected / exposed	0 / 5992 (0.00%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 4	
Pancreatic carcinoma metastatic			
subjects affected / exposed	0 / 5992 (0.00%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 3	
Pancreatic neuroendocrine tumour			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papillary serous endometrial carcinoma			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papillary thyroid cancer			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritoneal carcinoma metastatic			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pharyngeal cancer			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pituitary tumour benign			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasma cell myeloma			

subjects affected / exposed	1 / 5992 (0.02%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 2	
Polycythaemia vera			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer			
subjects affected / exposed	51 / 5992 (0.85%)	50 / 5995 (0.83%)	
occurrences causally related to treatment / all	0 / 51	1 / 50	
deaths causally related to treatment / all	0 / 1	0 / 1	
Prostate cancer metastatic			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Prostate cancer recurrent			
subjects affected / exposed	6 / 5992 (0.10%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Prostate cancer stage II			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic adenoma			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal adenocarcinoma			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal cancer			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal cancer metastatic			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectosigmoid cancer			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cancer			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cell carcinoma			
subjects affected / exposed	7 / 5992 (0.12%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal neoplasm			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland adenoma			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland cancer			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin cancer			

subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin squamous cell carcinoma metastatic			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small cell carcinoma			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Small cell lung cancer			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small cell lung cancer extensive stage			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Small cell lung cancer metastatic			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Squamous cell carcinoma			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of head and neck			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Squamous cell carcinoma of lung			

subjects affected / exposed	0 / 5992 (0.00%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 2	
Squamous cell carcinoma of skin			
subjects affected / exposed	5 / 5992 (0.08%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the oral cavity			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the tongue			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tongue neoplasm malignant stage unspecified			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsil cancer			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional cell carcinoma			
subjects affected / exposed	4 / 5992 (0.07%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteral neoplasm			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral cancer			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine cancer			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine leiomyoma			
subjects affected / exposed	3 / 5992 (0.05%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval cancer stage 0			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Waldenstrom's macroglobulinaemia			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Accelerated hypertension			
subjects affected / exposed	2 / 5992 (0.03%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic aneurysm			
subjects affected / exposed	11 / 5992 (0.18%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 11	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic dissection			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Aortic stenosis			

subjects affected / exposed	7 / 5992 (0.12%)	14 / 5995 (0.23%)	
occurrences causally related to treatment / all	0 / 7	1 / 15	
deaths causally related to treatment / all	0 / 0	0 / 1	
Arterial occlusive disease			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial stenosis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerosis			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Arteriovenous fistula			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Circulatory collapse			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	13 / 5992 (0.22%)	12 / 5995 (0.20%)	
occurrences causally related to treatment / all	0 / 16	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dry gangrene			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	14 / 5992 (0.23%)	10 / 5995 (0.17%)	
occurrences causally related to treatment / all	0 / 19	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hypertensive crisis			
subjects affected / exposed	7 / 5992 (0.12%)	8 / 5995 (0.13%)	
occurrences causally related to treatment / all	0 / 7	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive emergency			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	10 / 5992 (0.17%)	16 / 5995 (0.27%)	
occurrences causally related to treatment / all	0 / 10	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemic shock			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Iliac artery disease			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intermittent claudication			
subjects affected / exposed	2 / 5992 (0.03%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemia			

subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leriche syndrome			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoedema			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant hypertension			
subjects affected / exposed	3 / 5992 (0.05%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microscopic polyangiitis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			
subjects affected / exposed	1 / 5992 (0.02%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			
subjects affected / exposed	11 / 5992 (0.18%)	14 / 5995 (0.23%)	
occurrences causally related to treatment / all	0 / 11	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 1	
Peripheral artery aneurysm			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery dissection			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery occlusion			
subjects affected / exposed	4 / 5992 (0.07%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stenosis			
subjects affected / exposed	4 / 5992 (0.07%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery thrombosis			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral vascular disorder			
subjects affected / exposed	7 / 5992 (0.12%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 7	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral venous disease			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Poor peripheral circulation			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reperfusion injury			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shock haemorrhagic			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subclavian artery stenosis			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subclavian vein thrombosis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis superficial			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis limb			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Adverse drug reaction			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Asthenia		
subjects affected / exposed	5 / 5992 (0.08%)	9 / 5995 (0.15%)
occurrences causally related to treatment / all	0 / 5	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 0
Cardiac death		
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1
Chest discomfort		
subjects affected / exposed	7 / 5992 (0.12%)	6 / 5995 (0.10%)
occurrences causally related to treatment / all	0 / 7	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0
Chest pain		
subjects affected / exposed	21 / 5992 (0.35%)	16 / 5995 (0.27%)
occurrences causally related to treatment / all	0 / 22	0 / 16
deaths causally related to treatment / all	0 / 0	0 / 0
Complication associated with device		
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Cyst		
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Death		
subjects affected / exposed	12 / 5992 (0.20%)	16 / 5995 (0.27%)
occurrences causally related to treatment / all	1 / 12	2 / 16
deaths causally related to treatment / all	1 / 12	2 / 16
Drug withdrawal syndrome		

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exercise tolerance decreased			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatigue			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gait disturbance			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal complication associated with device			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Generalised oedema			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hernia pain			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypothermia			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired healing			

subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant site erosion			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated hernia			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infusion site extravasation			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Localised oedema			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaise			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device site haemorrhage			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple organ dysfunction syndrome			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Non-cardiac chest pain			

subjects affected / exposed	132 / 5992 (2.20%)	133 / 5995 (2.22%)	
occurrences causally related to treatment / all	0 / 153	1 / 164	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema peripheral			
subjects affected / exposed	4 / 5992 (0.07%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	1 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral swelling			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stent-graft endoleak			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden cardiac death			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 2	
Sudden death			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Systemic inflammatory response syndrome			

subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent occlusion			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent restenosis			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent thrombosis			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	4 / 5992 (0.07%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	1 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaphylactic shock			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug hypersensitivity			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypersensitivity			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Social circumstances			

Convalescent			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Spousal abuse			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Acquired hydrocele			
subjects affected / exposed	1 / 5992 (0.02%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adnexa uteri mass			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign prostatic hyperplasia			
subjects affected / exposed	10 / 5992 (0.17%)	7 / 5995 (0.12%)	
occurrences causally related to treatment / all	0 / 12	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast enlargement			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast fibrosis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast hyperplasia			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Breast pain			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast ulceration			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystocele			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial hyperplasia			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erectile dysfunction			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Female genital tract fistula			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Mastoptosis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orchitis noninfective			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Organic erectile dysfunction			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cyst			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic pain			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic prolapse			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Penis disorder			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postmenopausal haemorrhage			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Priapism			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatism			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatitis			

subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatomegaly			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scrotal haematocoele			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine polyp			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine prolapse			
subjects affected / exposed	4 / 5992 (0.07%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal haemorrhage			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal prolapse			
subjects affected / exposed	0 / 5992 (0.00%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	3 / 5992 (0.05%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory distress syndrome			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure			
subjects affected / exposed	28 / 5992 (0.47%)	35 / 5995 (0.58%)	
occurrences causally related to treatment / all	1 / 31	0 / 37	
deaths causally related to treatment / all	1 / 3	0 / 5	
Allergic bronchitis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspiration			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma			
subjects affected / exposed	9 / 5992 (0.15%)	12 / 5995 (0.20%)	
occurrences causally related to treatment / all	0 / 11	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atelectasis			
subjects affected / exposed	4 / 5992 (0.07%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial hyperreactivity			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis chronic			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchospasm			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	43 / 5992 (0.72%)	39 / 5995 (0.65%)	
occurrences causally related to treatment / all	0 / 53	0 / 58	
deaths causally related to treatment / all	0 / 3	0 / 0	
Chronic respiratory failure			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cough			
subjects affected / exposed	3 / 5992 (0.05%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	38 / 5992 (0.63%)	27 / 5995 (0.45%)	
occurrences causally related to treatment / all	1 / 40	0 / 27	
deaths causally related to treatment / all	0 / 1	0 / 0	
Dyspnoea exertional			
subjects affected / exposed	11 / 5992 (0.18%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 11	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Emphysema			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			
subjects affected / exposed	3 / 5992 (0.05%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			

subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemothorax			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hiccups			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercapnia			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	6 / 5992 (0.10%)	8 / 5995 (0.13%)	
occurrences causally related to treatment / all	0 / 6	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Idiopathic pulmonary fibrosis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interstitial lung disease			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal granuloma			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal mass			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung disorder			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Mediastinal haematoma			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mediastinal haemorrhage			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal obstruction			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal polyps			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive airways disorder			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal fistula			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pickwickian syndrome			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	10 / 5992 (0.17%)	12 / 5995 (0.20%)	
occurrences causally related to treatment / all	0 / 10	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleurisy			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleuritic pain			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			
subjects affected / exposed	4 / 5992 (0.07%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pneumonitis			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	4 / 5992 (0.07%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pulmonary arterial hypertension			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			

subjects affected / exposed	26 / 5992 (0.43%)	20 / 5995 (0.33%)	
occurrences causally related to treatment / all	1 / 27	0 / 21	
deaths causally related to treatment / all	0 / 1	0 / 3	
Pulmonary fibrosis			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pulmonary granuloma			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary haemorrhage			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary hypertension			
subjects affected / exposed	14 / 5992 (0.23%)	14 / 5995 (0.23%)	
occurrences causally related to treatment / all	4 / 14	1 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary mass			
subjects affected / exposed	4 / 5992 (0.07%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema			
subjects affected / exposed	8 / 5992 (0.13%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 8	0 / 5	
deaths causally related to treatment / all	0 / 2	0 / 0	
Pulmonary sarcoidosis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory arrest			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory distress			
subjects affected / exposed	3 / 5992 (0.05%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Respiratory failure			
subjects affected / exposed	14 / 5992 (0.23%)	14 / 5995 (0.23%)	
occurrences causally related to treatment / all	1 / 14	0 / 15	
deaths causally related to treatment / all	0 / 2	0 / 1	
Sleep apnoea syndrome			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachypnoea			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillar hypertrophy			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol abuse			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol withdrawal syndrome			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anger			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anxiety			
subjects affected / exposed	4 / 5992 (0.07%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Confusional state			
subjects affected / exposed	3 / 5992 (0.05%)	12 / 5995 (0.20%)	
occurrences causally related to treatment / all	0 / 3	1 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delirium			
subjects affected / exposed	3 / 5992 (0.05%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Depression			
subjects affected / exposed	5 / 5992 (0.08%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 5	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hallucination			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Insomnia			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Major depression			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental disorder due to a general medical condition			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			
subjects affected / exposed	6 / 5992 (0.10%)	10 / 5995 (0.17%)	
occurrences causally related to treatment / all	0 / 6	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nightmare			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post-traumatic stress disorder			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychotic disorder			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Somatic delusion			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicidal ideation			
subjects affected / exposed	4 / 5992 (0.07%)	9 / 5995 (0.15%)	
occurrences causally related to treatment / all	3 / 4	6 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
Device dislocation			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device failure			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device loosening			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device malfunction			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device pacing issue			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lead dislodgement			
subjects affected / exposed	0 / 5992 (0.00%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Autoimmune hepatitis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct obstruction			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct stone			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary colic			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary dyskinesia			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis			
subjects affected / exposed	3 / 5992 (0.05%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	1 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			
subjects affected / exposed	14 / 5992 (0.23%)	10 / 5995 (0.17%)	
occurrences causally related to treatment / all	1 / 14	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			
subjects affected / exposed	14 / 5992 (0.23%)	12 / 5995 (0.20%)	
occurrences causally related to treatment / all	0 / 14	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis chronic			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			

subjects affected / exposed	24 / 5992 (0.40%)	14 / 5995 (0.23%)	
occurrences causally related to treatment / all	0 / 25	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis obstructive			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic hepatic failure			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cirrhosis alcoholic			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cryptogenic cirrhosis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug-induced liver injury			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cirrhosis			
subjects affected / exposed	2 / 5992 (0.03%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 2	
Hepatic cyst			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic function abnormal			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic mass			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic steatosis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic vascular thrombosis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver disorder			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver injury			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-alcoholic fatty liver			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Portal vein thrombosis			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Ammonia increased			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic bruit			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood calcium decreased			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatinine increased			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood glucose increased			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood immunoglobulin G decreased			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood potassium increased			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure increased			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood sodium increased			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood urea increased			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood urine present			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Body temperature increased			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac stress test abnormal			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coagulation test abnormal			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ECG signs of myocardial ischaemia			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ejection fraction decreased			
subjects affected / exposed	1 / 5992 (0.02%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	1 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram QT prolonged			

subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram ST segment depression			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram abnormal			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glycosylated haemoglobin increased			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoglobin decreased			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heart rate decreased			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic enzyme increased			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
International normalised ratio abnormal			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
International normalised ratio increased			

subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test abnormal			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test increased			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
N-terminal prohormone brain natriuretic peptide increased			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oxygen saturation decreased			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Platelet count decreased			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic specific antigen increased			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prothrombin time prolonged			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary arterial pressure increased			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin T increased			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin increased			
subjects affected / exposed	8 / 5992 (0.13%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 8	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
White blood cell count increased			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Abdominal injury			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Accidental overdose			
subjects affected / exposed	1 / 5992 (0.02%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol poisoning			
subjects affected / exposed	2 / 5992 (0.03%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 2	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia postoperative			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anastomotic ulcer haemorrhage			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Animal bite			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankle fracture			
subjects affected / exposed	4 / 5992 (0.07%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial bypass thrombosis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial injury			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder injury			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain contusion			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardiac contusion			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac valve replacement complication			

subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cartilage injury			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical vertebral fracture			
subjects affected / exposed	2 / 5992 (0.03%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest injury			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clavicle fracture			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Concussion			
subjects affected / exposed	1 / 5992 (0.02%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion			
subjects affected / exposed	3 / 5992 (0.05%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis radiation			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delayed recovery from anaesthesia			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extradural haematoma			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial bones fracture			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	15 / 5992 (0.25%)	21 / 5995 (0.35%)	
occurrences causally related to treatment / all	0 / 17	0 / 21	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral neck fracture			
subjects affected / exposed	4 / 5992 (0.07%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	2 / 5992 (0.03%)	10 / 5995 (0.17%)	
occurrences causally related to treatment / all	0 / 2	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibula fracture			
subjects affected / exposed	3 / 5992 (0.05%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot fracture			

subjects affected / exposed	3 / 5992 (0.05%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Forearm fracture			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fractured sacrum			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal stoma complication			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hand fracture			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Head injury			
subjects affected / exposed	2 / 5992 (0.03%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip fracture			
subjects affected / exposed	5 / 5992 (0.08%)	10 / 5995 (0.17%)	
occurrences causally related to treatment / all	0 / 5	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	6 / 5992 (0.10%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ilium fracture			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated incisional hernia			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incision site complication			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incision site haemorrhage			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incisional hernia			
subjects affected / exposed	3 / 5992 (0.05%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incomplete spinal fusion			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intentional overdose			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal anastomosis complication			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaw fracture			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint capsule rupture			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation			
subjects affected / exposed	3 / 5992 (0.05%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation postoperative			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint injury			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kidney contusion			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laceration			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament rupture			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament sprain			

subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb injury			
subjects affected / exposed	3 / 5992 (0.05%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb traumatic amputation			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver contusion			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower limb fracture			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			
subjects affected / exposed	1 / 5992 (0.02%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus injury			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes postoperative			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple fractures			

subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple injuries			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle strain			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patella fracture			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic fracture			
subjects affected / exposed	3 / 5992 (0.05%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periprosthetic fracture			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis chemical			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax traumatic			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post laminectomy syndrome			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural bile leak			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural complication			
subjects affected / exposed	3 / 5992 (0.05%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Post procedural discharge			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematoma			
subjects affected / exposed	2 / 5992 (0.03%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematuria			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage			
subjects affected / exposed	3 / 5992 (0.05%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural myocardial infarction			
subjects affected / exposed	3 / 5992 (0.05%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural swelling			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative fever			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative ileus			
subjects affected / exposed	1 / 5992 (0.02%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative renal failure			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative respiratory failure			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative thoracic procedure complication			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound complication			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postpericardiotomy syndrome			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural complication			

subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural haemorrhage			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural hypotension			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural pain			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural pneumothorax			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pubis fracture			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary contusion			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radius fracture			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			

subjects affected / exposed	9 / 5992 (0.15%)	9 / 5995 (0.15%)	
occurrences causally related to treatment / all	0 / 9	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	9 / 5992 (0.15%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	1 / 9	0 / 5	
deaths causally related to treatment / all	0 / 2	0 / 3	
Scapula fracture			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seroma			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shunt malfunction			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shunt occlusion			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin abrasion			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull fracture			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture			

subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fracture			
subjects affected / exposed	3 / 5992 (0.05%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic rupture			
subjects affected / exposed	1 / 5992 (0.02%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Stab wound			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	7 / 5992 (0.12%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 8	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 0	
Tendon rupture			
subjects affected / exposed	1 / 5992 (0.02%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	3 / 5992 (0.05%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic arthritis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic haematoma			

subjects affected / exposed	4 / 5992 (0.07%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic haemorrhage			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic haemothorax			
subjects affected / exposed	3 / 5992 (0.05%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic intracranial haemorrhage			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper limb fracture			
subjects affected / exposed	4 / 5992 (0.07%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention postoperative			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular pseudoaneurysm			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular pseudoaneurysm ruptured			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Weaning failure			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound dehiscence			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Wound haematoma			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wrist fracture			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Atrial septal defect			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Choledochal cyst			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Developmental hip dysplasia			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal arteriovenous malformation			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocele			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertrophic cardiomyopathy			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microgenia			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	14 / 5992 (0.23%)	11 / 5995 (0.18%)	
occurrences causally related to treatment / all	0 / 14	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute left ventricular failure			
subjects affected / exposed	3 / 5992 (0.05%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			
subjects affected / exposed	117 / 5992 (1.95%)	105 / 5995 (1.75%)	
occurrences causally related to treatment / all	1 / 131	0 / 118	
deaths causally related to treatment / all	1 / 7	0 / 3	
Angina pectoris			
subjects affected / exposed	123 / 5992 (2.05%)	142 / 5995 (2.37%)	
occurrences causally related to treatment / all	0 / 136	0 / 152	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable			

subjects affected / exposed	106 / 5992 (1.77%)	113 / 5995 (1.88%)	
occurrences causally related to treatment / all	1 / 115	0 / 129	
deaths causally related to treatment / all	0 / 1	0 / 0	
Anginal equivalent			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve disease			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve incompetence			
subjects affected / exposed	4 / 5992 (0.07%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	1 / 4	2 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve stenosis			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	1 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Arteriosclerosis coronary artery			
subjects affected / exposed	1 / 5992 (0.02%)	9 / 5995 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 1	
Arteriospasm coronary			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			

subjects affected / exposed	102 / 5992 (1.70%)	105 / 5995 (1.75%)	
occurrences causally related to treatment / all	2 / 122	3 / 120	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial flutter			
subjects affected / exposed	22 / 5992 (0.37%)	21 / 5995 (0.35%)	
occurrences causally related to treatment / all	0 / 28	3 / 23	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial tachycardia			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block			
subjects affected / exposed	0 / 5992 (0.00%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block complete			
subjects affected / exposed	7 / 5992 (0.12%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	1 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block first degree			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block second degree			
subjects affected / exposed	3 / 5992 (0.05%)	7 / 5995 (0.12%)	
occurrences causally related to treatment / all	1 / 3	1 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradyarrhythmia			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			

subjects affected / exposed	17 / 5992 (0.28%)	18 / 5995 (0.30%)	
occurrences causally related to treatment / all	0 / 17	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 1	
Bundle branch block bilateral			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block left			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block right			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac aneurysm			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	19 / 5992 (0.32%)	17 / 5995 (0.28%)	
occurrences causally related to treatment / all	0 / 19	0 / 17	
deaths causally related to treatment / all	0 / 11	0 / 11	
Cardiac discomfort			
subjects affected / exposed	7 / 5992 (0.12%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorder			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardiac failure			

subjects affected / exposed	21 / 5992 (0.35%)	18 / 5995 (0.30%)	
occurrences causally related to treatment / all	0 / 25	0 / 19	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cardiac failure acute			
subjects affected / exposed	5 / 5992 (0.08%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure chronic			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive			
subjects affected / exposed	106 / 5992 (1.77%)	91 / 5995 (1.52%)	
occurrences causally related to treatment / all	2 / 139	3 / 124	
deaths causally related to treatment / all	1 / 3	0 / 1	
Cardiac perforation			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac tamponade			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac valve disease			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac ventricular thrombosis			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardio-respiratory arrest			

subjects affected / exposed	6 / 5992 (0.10%)	7 / 5995 (0.12%)	
occurrences causally related to treatment / all	0 / 6	1 / 7	
deaths causally related to treatment / all	0 / 5	1 / 6	
Cardiogenic shock			
subjects affected / exposed	5 / 5992 (0.08%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	1 / 5	0 / 4	
deaths causally related to treatment / all	1 / 3	0 / 2	
Cardiomyopathy			
subjects affected / exposed	4 / 5992 (0.07%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiopulmonary failure			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 1	
Cardiovascular disorder			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cardiovascular insufficiency			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cor pulmonale			
subjects affected / exposed	1 / 5992 (0.02%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cor pulmonale acute			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cor pulmonale chronic			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease			
subjects affected / exposed	78 / 5992 (1.30%)	87 / 5995 (1.45%)	
occurrences causally related to treatment / all	0 / 80	3 / 92	
deaths causally related to treatment / all	0 / 0	0 / 8	
Coronary artery occlusion			
subjects affected / exposed	6 / 5992 (0.10%)	8 / 5995 (0.13%)	
occurrences causally related to treatment / all	0 / 6	1 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery perforation			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery stenosis			
subjects affected / exposed	13 / 5992 (0.22%)	17 / 5995 (0.28%)	
occurrences causally related to treatment / all	0 / 13	1 / 17	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diastolic dysfunction			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperdynamic left ventricle			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive heart disease			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Intracardiac thrombus			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic cardiomyopathy			
subjects affected / exposed	4 / 5992 (0.07%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kounis syndrome			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left atrial dilatation			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular dysfunction			
subjects affected / exposed	3 / 5992 (0.05%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	1 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular failure			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microvascular coronary artery disease			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve disease			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve incompetence			

subjects affected / exposed	12 / 5992 (0.20%)	12 / 5995 (0.20%)	
occurrences causally related to treatment / all	3 / 12	4 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve prolapse			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve stenosis			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	31 / 5992 (0.52%)	36 / 5995 (0.60%)	
occurrences causally related to treatment / all	2 / 31	0 / 38	
deaths causally related to treatment / all	1 / 9	0 / 4	
Myocardial ischaemia			
subjects affected / exposed	16 / 5992 (0.27%)	14 / 5995 (0.23%)	
occurrences causally related to treatment / all	1 / 17	1 / 14	
deaths causally related to treatment / all	0 / 0	1 / 3	
Palpitations			
subjects affected / exposed	5 / 5992 (0.08%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial cyst			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			
subjects affected / exposed	0 / 5992 (0.00%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial haemorrhage			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis constrictive			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prinzmetal angina			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary valve incompetence			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulseless electrical activity			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	1 / 1	
deaths causally related to treatment / all	0 / 1	1 / 1	
Right ventricular failure			
subjects affected / exposed	1 / 5992 (0.02%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus bradycardia			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus node dysfunction			

subjects affected / exposed	6 / 5992 (0.10%)	15 / 5995 (0.25%)	
occurrences causally related to treatment / all	0 / 6	0 / 17	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus tachycardia			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress cardiomyopathy			
subjects affected / exposed	0 / 5992 (0.00%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Supraventricular tachycardia			
subjects affected / exposed	9 / 5992 (0.15%)	11 / 5995 (0.18%)	
occurrences causally related to treatment / all	0 / 9	1 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Systolic dysfunction			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia			
subjects affected / exposed	1 / 5992 (0.02%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tricuspid valve incompetence			
subjects affected / exposed	7 / 5992 (0.12%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	3 / 7	2 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular arrhythmia			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular extrasystoles			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular fibrillation			
subjects affected / exposed	8 / 5992 (0.13%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 8	0 / 4	
deaths causally related to treatment / all	0 / 2	0 / 0	
Ventricular tachyarrhythmia			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular tachycardia			
subjects affected / exposed	22 / 5992 (0.37%)	13 / 5995 (0.22%)	
occurrences causally related to treatment / all	0 / 27	0 / 14	
deaths causally related to treatment / all	0 / 1	0 / 0	
Nervous system disorders			
Amnesia			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ataxia			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Balance disorder			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal ganglia haemorrhage			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Basal ganglia infarction			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bickerstaff's encephalitis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain injury			
subjects affected / exposed	3 / 5992 (0.05%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 1	
Brain stem haemorrhage			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Brain stem infarction			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain stem stroke			
subjects affected / exposed	3 / 5992 (0.05%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery disease			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery occlusion			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery stenosis			

subjects affected / exposed	17 / 5992 (0.28%)	15 / 5995 (0.25%)	
occurrences causally related to treatment / all	0 / 19	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid sinus syndrome			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carpal tunnel syndrome			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Central nervous system necrosis			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar infarction			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral circulatory failure			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haemorrhage			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral infarction			
subjects affected / exposed	4 / 5992 (0.07%)	9 / 5995 (0.15%)	
occurrences causally related to treatment / all	0 / 4	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrospinal fluid leakage			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	41 / 5992 (0.68%)	29 / 5995 (0.48%)	
occurrences causally related to treatment / all	3 / 42	1 / 31	
deaths causally related to treatment / all	0 / 3	0 / 2	
Cerebrovascular disorder			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical cord compression			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical myelopathy			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical radiculopathy			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervicogenic headache			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Complex partial seizures			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cranial nerve palsies multiple			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cubital tunnel syndrome			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Dementia Alzheimer's type			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic coma			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	9 / 5992 (0.15%)	14 / 5995 (0.23%)	
occurrences causally related to treatment / all	0 / 9	2 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness postural			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysarthria			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolic cerebral infarction			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embololic stroke			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalopathy			
subjects affected / exposed	2 / 5992 (0.03%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epilepsy			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial paralysis			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Frontal lobe epilepsy			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Guillain-Barre syndrome			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage intracranial			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic stroke			

subjects affected / exposed	1 / 5992 (0.02%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 2	
Headache			
subjects affected / exposed	9 / 5992 (0.15%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	1 / 10	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiparesis			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic encephalopathy			
subjects affected / exposed	0 / 5992 (0.00%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive encephalopathy			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoaesthesia			
subjects affected / exposed	5 / 5992 (0.08%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxic-ischaemic encephalopathy			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	1 / 1	
IIIrd nerve paralysis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial aneurysm			

subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Ischaemic stroke			
subjects affected / exposed	14 / 5992 (0.23%)	13 / 5995 (0.22%)	
occurrences causally related to treatment / all	0 / 14	1 / 14	
deaths causally related to treatment / all	0 / 1	0 / 1	
Lacunar infarction			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			
subjects affected / exposed	3 / 5992 (0.05%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar radiculopathy			
subjects affected / exposed	4 / 5992 (0.07%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbosacral radiculopathy			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic encephalopathy			
subjects affected / exposed	2 / 5992 (0.03%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Migraine			
subjects affected / exposed	5 / 5992 (0.08%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 5	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Migraine with aura			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Motor neurone disease			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myasthenia gravis			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelomalacia			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelopathy			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myoclonus			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nerve compression			
subjects affected / exposed	0 / 5992 (0.00%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nerve root compression			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuralgia			

subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuromyelitis optica spectrum disorder			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathy peripheral			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normal pressure hydrocephalus			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraesthesia			
subjects affected / exposed	1 / 5992 (0.02%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parkinson's disease			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parkinsonism			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peroneal nerve palsy			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Petit mal epilepsy			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	13 / 5992 (0.22%)	9 / 5995 (0.15%)	
occurrences causally related to treatment / all	0 / 13	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radial nerve palsy			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radicular pain			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sciatica			
subjects affected / exposed	7 / 5992 (0.12%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	4 / 5992 (0.07%)	10 / 5995 (0.17%)	
occurrences causally related to treatment / all	0 / 4	0 / 13	
deaths causally related to treatment / all	0 / 1	0 / 0	
Serotonin syndrome			
subjects affected / exposed	3 / 5992 (0.05%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	4 / 4	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Simple partial seizures			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Slow speech			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Somnolence			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal claudication			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord disorder			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylitic myelopathy			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage			
subjects affected / exposed	2 / 5992 (0.03%)	9 / 5995 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 2	
Superficial siderosis of central nervous system			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Superior sagittal sinus thrombosis			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	49 / 5992 (0.82%)	54 / 5995 (0.90%)	
occurrences causally related to treatment / all	3 / 51	1 / 62	
deaths causally related to treatment / all	0 / 0	0 / 1	
Thalamus haemorrhage			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic encephalopathy			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient global amnesia			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	1 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	38 / 5992 (0.63%)	46 / 5995 (0.77%)	
occurrences causally related to treatment / all	0 / 39	3 / 55	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transverse sinus thrombosis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tremor			
subjects affected / exposed	0 / 5992 (0.00%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Trigeminal neuralgia			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Unresponsive to stimuli			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VIth nerve paralysis			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral artery dissection			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral artery thrombosis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebrobasilar insufficiency			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vocal cord paralysis			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Abdominal lymphadenopathy			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia			

subjects affected / exposed	19 / 5992 (0.32%)	12 / 5995 (0.20%)	
occurrences causally related to treatment / all	0 / 19	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia macrocytic			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autoimmune haemolytic anaemia			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Disseminated intravascular coagulation			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic anaemia			
subjects affected / exposed	7 / 5992 (0.12%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron deficiency anaemia			
subjects affected / exposed	2 / 5992 (0.03%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukocytosis			
subjects affected / exposed	3 / 5992 (0.05%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukopenia			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microcytic anaemia			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normochromic normocytic anaemia			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic haematoma			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic infarction			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spontaneous haematoma			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			

subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Tympanic membrane perforation			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo			
subjects affected / exposed	8 / 5992 (0.13%)	9 / 5995 (0.15%)	
occurrences causally related to treatment / all	0 / 8	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo positional			
subjects affected / exposed	1 / 5992 (0.02%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Cataract			
subjects affected / exposed	3 / 5992 (0.05%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Charles Bonnet syndrome			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deformity of orbit			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular oedema			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oscillopsia			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal artery occlusion			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal vascular thrombosis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vision blurred			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous adhesions			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous haemorrhage			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal adhesions			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal discomfort			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal distension			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal fat apron			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal hernia			
subjects affected / exposed	10 / 5992 (0.17%)	7 / 5995 (0.12%)	
occurrences causally related to treatment / all	0 / 10	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal hernia obstructive			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal incarcerated hernia			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	11 / 5992 (0.18%)	9 / 5995 (0.15%)	
occurrences causally related to treatment / all	1 / 11	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	7 / 5992 (0.12%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 7	1 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal wall haematoma			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fissure			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal incontinence			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anorectal varices			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coeliac artery stenosis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	8 / 5992 (0.13%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 8	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ischaemic			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis microscopic			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ulcerative			

subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colonic pseudo-obstruction			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	6 / 5992 (0.10%)	8 / 5995 (0.13%)	
occurrences causally related to treatment / all	0 / 7	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Crohn's disease			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	6 / 5992 (0.10%)	8 / 5995 (0.13%)	
occurrences causally related to treatment / all	1 / 6	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dieulafoy's vascular malformation			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticular perforation			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum			
subjects affected / exposed	4 / 5992 (0.07%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum intestinal haemorrhagic			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer haemorrhage			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer perforation			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenitis			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenogastric reflux			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspepsia			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			
subjects affected / exposed	6 / 5992 (0.10%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis			

subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocoele			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erosive duodenitis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erosive oesophagitis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Faecaloma			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Food poisoning			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric antral vascular ectasia			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric disorder			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric haemorrhage			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gastric perforation			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric polyps			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer			
subjects affected / exposed	5 / 5992 (0.08%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer haemorrhage			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	6 / 5992 (0.10%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 7	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis erosive			
subjects affected / exposed	3 / 5992 (0.05%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal angiodysplasia haemorrhagic			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			

subjects affected / exposed	27 / 5992 (0.45%)	29 / 5995 (0.48%)	
occurrences causally related to treatment / all	0 / 30	0 / 29	
deaths causally related to treatment / all	0 / 1	0 / 1	
Gastrointestinal necrosis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal ulcer haemorrhage			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrooesophageal reflux disease			
subjects affected / exposed	9 / 5992 (0.15%)	11 / 5995 (0.18%)	
occurrences causally related to treatment / all	0 / 10	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematochezia			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoidal haemorrhage			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hiatus hernia			
subjects affected / exposed	5 / 5992 (0.08%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			

subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired gastric emptying			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated umbilical hernia			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	9 / 5992 (0.15%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 9	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal dilatation			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal haemorrhage			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal ischaemia			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	3 / 5992 (0.05%)	7 / 5995 (0.12%)	
occurrences causally related to treatment / all	0 / 3	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal perforation			

subjects affected / exposed	3 / 5992 (0.05%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intra-abdominal haematoma			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Irritable bowel syndrome			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal haemorrhage			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal ulcer			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine perforation			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine polyp			
subjects affected / exposed	2 / 5992 (0.03%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower gastrointestinal haemorrhage			
subjects affected / exposed	9 / 5992 (0.15%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 9	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Megacolon			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melaena			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesenteric artery stenosis			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesenteric panniculitis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	3 / 5992 (0.05%)	8 / 5995 (0.13%)	
occurrences causally related to treatment / all	0 / 3	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstruction gastric			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Odynophagia			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal food impaction			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal pain			

subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal spasm			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal stenosis			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal varices haemorrhage			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Omental infarction			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	14 / 5992 (0.23%)	13 / 5995 (0.22%)	
occurrences causally related to treatment / all	5 / 15	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	15 / 5992 (0.25%)	9 / 5995 (0.15%)	
occurrences causally related to treatment / all	0 / 17	0 / 9	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pancreatitis chronic			

subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis relapsing			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peptic ulcer			
subjects affected / exposed	3 / 5992 (0.05%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peptic ulcer haemorrhage			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	6 / 5992 (0.10%)	8 / 5995 (0.13%)	
occurrences causally related to treatment / all	0 / 6	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal polyp			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal haemorrhage			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland mass			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			

subjects affected / exposed	18 / 5992 (0.30%)	11 / 5995 (0.18%)	
occurrences causally related to treatment / all	0 / 22	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tongue disorder			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia			
subjects affected / exposed	7 / 5992 (0.12%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 7	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	5 / 5992 (0.08%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uvulitis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Visceroptosis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	7 / 5992 (0.12%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 7	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decubitus ulcer			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis atopic			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot			
subjects affected / exposed	4 / 5992 (0.07%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ulcer			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug reaction with eosinophilia and systemic symptoms			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Excessive skin			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperhidrosis			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypersensitivity vasculitis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutrophilic dermatosis			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Petechiae			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pruritus			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash erythematous			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin necrosis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin ulcer			
subjects affected / exposed	5 / 5992 (0.08%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Telangiectasia			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urticaria			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	57 / 5992 (0.95%)	57 / 5995 (0.95%)	
occurrences causally related to treatment / all	1 / 64	0 / 61	
deaths causally related to treatment / all	0 / 2	0 / 1	
Acute prerenal failure			
subjects affected / exposed	3 / 5992 (0.05%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Albuminuria			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Azotaemia			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder disorder			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder dysfunction			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neck obstruction			
subjects affected / exposed	3 / 5992 (0.05%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder necrosis			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder outlet obstruction			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder prolapse			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder stenosis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus urinary			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic kidney disease			
subjects affected / exposed	5 / 5992 (0.08%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cystitis haemorrhagic			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic nephropathy			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
End stage renal disease			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	7 / 5992 (0.12%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 10	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage urinary tract			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydronephrosis			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower urinary tract symptoms			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	18 / 5992 (0.30%)	11 / 5995 (0.18%)	
occurrences causally related to treatment / all	0 / 18	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive uropathy			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oliguria			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proteinuria			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery stenosis			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal colic			
subjects affected / exposed	2 / 5992 (0.03%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	3 / 5992 (0.05%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Renal haemorrhage			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal impairment			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal infarct			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal mass			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal tubular necrosis			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteral disorder			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureterocele			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureterolithiasis			
subjects affected / exposed	6 / 5992 (0.10%)	7 / 5995 (0.12%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral stenosis			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary bladder haemorrhage			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			
subjects affected / exposed	6 / 5992 (0.10%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 9	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract obstruction			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Adrenal insufficiency			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Goitre			
subjects affected / exposed	1 / 5992 (0.02%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperparathyroidism			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperthyroidism			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypothyroidism			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid mass			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyrotoxic crisis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	25 / 5992 (0.42%)	25 / 5995 (0.42%)	
occurrences causally related to treatment / all	0 / 26	0 / 26	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis			

subjects affected / exposed	16 / 5992 (0.27%)	19 / 5995 (0.32%)	
occurrences causally related to treatment / all	0 / 19	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis reactive			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthropathy			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	15 / 5992 (0.25%)	16 / 5995 (0.27%)	
occurrences causally related to treatment / all	0 / 15	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical spinal stenosis			
subjects affected / exposed	8 / 5992 (0.13%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 8	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chondrocalcinosis pyrophosphate			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Costochondritis			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exostosis			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibromyalgia			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Flank pain			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot deformity			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fracture delayed union			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fracture malunion			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fracture nonunion			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gouty arthritis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemarthrosis			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc compression			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc degeneration			
subjects affected / exposed	5 / 5992 (0.08%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc displacement			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	15 / 5992 (0.25%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 15	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc space narrowing			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb discomfort			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar spinal stenosis			
subjects affected / exposed	13 / 5992 (0.22%)	12 / 5995 (0.20%)	
occurrences causally related to treatment / all	0 / 13	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mobility decreased			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Monarthritis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle spasms			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscular weakness			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			
subjects affected / exposed	13 / 5992 (0.22%)	10 / 5995 (0.17%)	
occurrences causally related to treatment / all	0 / 13	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal pain			
subjects affected / exposed	7 / 5992 (0.12%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myalgia			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myositis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck mass			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck pain			
subjects affected / exposed	3 / 5992 (0.05%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathic arthropathy			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	109 / 5992 (1.82%)	93 / 5995 (1.55%)	
occurrences causally related to treatment / all	0 / 121	0 / 97	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthropathy			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteolysis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteonecrosis			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoporosis			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			

subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in jaw			
subjects affected / exposed	1 / 5992 (0.02%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pathological fracture			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plantar fasciitis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyarthritis			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polymyalgia rheumatica			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyolysis			
subjects affected / exposed	3 / 5992 (0.05%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 3	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatoid arthritis			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotator cuff syndrome			

subjects affected / exposed	10 / 5992 (0.17%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 10	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scoliosis			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue mass			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal column stenosis			
subjects affected / exposed	10 / 5992 (0.17%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 11	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal osteoarthritis			
subjects affected / exposed	7 / 5992 (0.12%)	10 / 5995 (0.17%)	
occurrences causally related to treatment / all	0 / 8	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal pain			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylitis			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylolisthesis			
subjects affected / exposed	5 / 5992 (0.08%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Synovial cyst			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral foraminal stenosis			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral osteophyte			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	3 / 5992 (0.05%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal wall abscess			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess limb			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess neck			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess of salivary gland			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute sinusitis			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal abscess			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	9 / 5992 (0.15%)	9 / 5995 (0.15%)	
occurrences causally related to treatment / all	0 / 9	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis perforated			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis bacterial			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis infective			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	6 / 5992 (0.10%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial infection			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial sepsis			

subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone abscess			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchiolitis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	26 / 5992 (0.43%)	18 / 5995 (0.30%)	
occurrences causally related to treatment / all	0 / 26	0 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis viral			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Campylobacter infection			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Campylobacter sepsis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Catheter site infection			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			

subjects affected / exposed	71 / 5992 (1.18%)	48 / 5995 (0.80%)	
occurrences causally related to treatment / all	0 / 81	2 / 52	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis pasteurella			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis staphylococcal			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis streptococcal			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis infective			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic sinusitis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic tonsillitis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			

subjects affected / exposed	2 / 5992 (0.03%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colonic abscess			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dengue fever			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	7 / 5992 (0.12%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 8	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related sepsis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot infection			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic gangrene			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea infectious			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	17 / 5992 (0.28%)	23 / 5995 (0.38%)	
occurrences causally related to treatment / all	0 / 22	0 / 26	
deaths causally related to treatment / all	0 / 0	0 / 0	
Emphysematous cystitis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Empyema			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalitis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis			
subjects affected / exposed	1 / 5992 (0.02%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterococcal bacteraemia			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epididymitis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia bacteraemia			

subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia infection			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia sepsis			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia urinary tract infection			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extradural abscess			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gangrene			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	13 / 5992 (0.22%)	10 / 5995 (0.17%)	
occurrences causally related to treatment / all	0 / 13	1 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis bacterial			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			

subjects affected / exposed	3 / 5992 (0.05%)	7 / 5995 (0.12%)	
occurrences causally related to treatment / all	0 / 3	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Groin abscess			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Groin infection			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
H1N1 influenza			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis A			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis B			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Human anaplasmosis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Human ehrlichiosis			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant site infection			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incision site abscess			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incision site infection			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected skin ulcer			
subjects affected / exposed	3 / 5992 (0.05%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infectious colitis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infectious pleural effusion			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective tenosynovitis			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	10 / 5992 (0.17%)	12 / 5995 (0.20%)	
occurrences causally related to treatment / all	0 / 10	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kidney infection			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Klebsiella bacteraemia			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Labyrinthitis			
subjects affected / exposed	1 / 5992 (0.02%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngitis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Localised infection			
subjects affected / exposed	5 / 5992 (0.08%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	3 / 5992 (0.05%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection viral			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lyme disease			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphangitis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mastoiditis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrotising fasciitis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenic sepsis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal candidiasis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orchitis			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			

subjects affected / exposed	13 / 5992 (0.22%)	11 / 5995 (0.18%)	
occurrences causally related to treatment / all	0 / 14	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis acute			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parainfluenzae virus infection			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraspinal abscess			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic abscess			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perirectal abscess			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis bacterial			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal abscess			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis			

subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	86 / 5992 (1.44%)	92 / 5995 (1.53%)	
occurrences causally related to treatment / all	1 / 90	0 / 105	
deaths causally related to treatment / all	0 / 3	0 / 2	
Pneumonia bacterial			
subjects affected / exposed	3 / 5992 (0.05%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia legionella			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia mycoplasmal			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia pneumococcal			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia staphylococcal			
subjects affected / exposed	3 / 5992 (0.05%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia streptococcal			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia viral			

subjects affected / exposed	4 / 5992 (0.07%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural cellulitis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural infection			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative abscess			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			
subjects affected / exposed	1 / 5992 (0.02%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pulmonary sepsis			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	4 / 5992 (0.07%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			
subjects affected / exposed	4 / 5992 (0.07%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory moniliasis			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection viral			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rocky mountain spotted fever			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotavirus infection			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scrotal abscess			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	27 / 5992 (0.45%)	37 / 5995 (0.62%)	
occurrences causally related to treatment / all	0 / 27	0 / 39	
deaths causally related to treatment / all	0 / 3	0 / 4	
Sepsis syndrome			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic arthritis staphylococcal			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic embolus			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	5 / 5992 (0.08%)	7 / 5995 (0.12%)	
occurrences causally related to treatment / all	0 / 5	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 2	
Sialoadenitis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinusitis			
subjects affected / exposed	3 / 5992 (0.05%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal bacteraemia			
subjects affected / exposed	2 / 5992 (0.03%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal infection			
subjects affected / exposed	3 / 5992 (0.05%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal osteomyelitis			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal sepsis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal skin infection			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Streptococcal bacteraemia			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Streptococcal infection			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous abscess			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillitis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth abscess			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth infection			

subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheobronchitis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	3 / 5992 (0.05%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	1 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	40 / 5992 (0.67%)	30 / 5995 (0.50%)	
occurrences causally related to treatment / all	2 / 41	0 / 30	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection bacterial			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection enterococcal			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	7 / 5992 (0.12%)	13 / 5995 (0.22%)	
occurrences causally related to treatment / all	0 / 7	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent infection			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vestibular neuronitis			

subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
subjects affected / exposed	2 / 5992 (0.03%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral upper respiratory tract infection			
subjects affected / exposed	2 / 5992 (0.03%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulvitis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
West Nile viral infection			
subjects affected / exposed	0 / 5992 (0.00%)	2 / 5995 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound abscess			
subjects affected / exposed	1 / 5992 (0.02%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			
subjects affected / exposed	4 / 5992 (0.07%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection pseudomonas			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection staphylococcal			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Acidosis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholesterosis			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decreased appetite			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	21 / 5992 (0.35%)	13 / 5995 (0.22%)	
occurrences causally related to treatment / all	0 / 21	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus			
subjects affected / exposed	13 / 5992 (0.22%)	11 / 5995 (0.18%)	
occurrences causally related to treatment / all	0 / 13	1 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus inadequate control			
subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			
subjects affected / exposed	4 / 5992 (0.07%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 1	
Electrolyte imbalance			

subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fluid overload			
subjects affected / exposed	5 / 5992 (0.08%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gout			
subjects affected / exposed	6 / 5992 (0.10%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	0 / 5992 (0.00%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	1 / 5992 (0.02%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	11 / 5992 (0.18%)	6 / 5995 (0.10%)	
occurrences causally related to treatment / all	1 / 11	0 / 6	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hyperosmolar hyperglycaemic state			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperosmolar state			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperphosphataemia			

subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypocalcaemia			
subjects affected / exposed	0 / 5992 (0.00%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			
subjects affected / exposed	7 / 5992 (0.12%)	18 / 5995 (0.30%)	
occurrences causally related to treatment / all	1 / 7	3 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	5 / 5992 (0.08%)	10 / 5995 (0.17%)	
occurrences causally related to treatment / all	0 / 6	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypomagnesaemia			
subjects affected / exposed	1 / 5992 (0.02%)	4 / 5995 (0.07%)	
occurrences causally related to treatment / all	1 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	4 / 5992 (0.07%)	5 / 5995 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypophagia			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemia			
subjects affected / exposed	0 / 5992 (0.00%)	3 / 5995 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lactic acidosis			

subjects affected / exposed	1 / 5992 (0.02%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malnutrition			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic acidosis			
subjects affected / exposed	2 / 5992 (0.03%)	0 / 5995 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obesity			
subjects affected / exposed	12 / 5992 (0.20%)	12 / 5995 (0.20%)	
occurrences causally related to treatment / all	0 / 12	0 / 12	
deaths causally related to treatment / all	0 / 1	0 / 0	
Type 2 diabetes mellitus			
subjects affected / exposed	11 / 5992 (0.18%)	7 / 5995 (0.12%)	
occurrences causally related to treatment / all	0 / 11	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitamin D deficiency			
subjects affected / exposed	0 / 5992 (0.00%)	1 / 5995 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo	Lorcaserin 10 mg	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4788 / 5992 (79.91%)	4946 / 5995 (82.50%)	
Nervous system disorders			
Dizziness			
subjects affected / exposed	340 / 5992 (5.67%)	537 / 5995 (8.96%)	
occurrences (all)	407	640	
Headache			

subjects affected / exposed occurrences (all)	274 / 5992 (4.57%) 316	383 / 5995 (6.39%) 445	
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	302 / 5992 (5.04%)	496 / 5995 (8.27%)	
occurrences (all)	329	548	
Oedema peripheral			
subjects affected / exposed	340 / 5992 (5.67%)	267 / 5995 (4.45%)	
occurrences (all)	385	294	
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	248 / 5992 (4.14%)	336 / 5995 (5.60%)	
occurrences (all)	268	362	
Diarrhoea			
subjects affected / exposed	324 / 5992 (5.41%)	419 / 5995 (6.99%)	
occurrences (all)	362	478	
Nausea			
subjects affected / exposed	286 / 5992 (4.77%)	356 / 5995 (5.94%)	
occurrences (all)	329	398	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	303 / 5992 (5.06%)	376 / 5995 (6.27%)	
occurrences (all)	351	431	
Dyspnoea			
subjects affected / exposed	310 / 5992 (5.17%)	285 / 5995 (4.75%)	
occurrences (all)	347	312	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	452 / 5992 (7.54%)	457 / 5995 (7.62%)	
occurrences (all)	542	544	
Back pain			
subjects affected / exposed	452 / 5992 (7.54%)	457 / 5995 (7.62%)	
occurrences (all)	496	496	
Infections and infestations			

Bronchitis			
subjects affected / exposed	468 / 5992 (7.81%)	455 / 5995 (7.59%)	
occurrences (all)	584	536	
Nasopharyngitis			
subjects affected / exposed	338 / 5992 (5.64%)	353 / 5995 (5.89%)	
occurrences (all)	418	426	
Upper respiratory tract infection			
subjects affected / exposed	567 / 5992 (9.46%)	528 / 5995 (8.81%)	
occurrences (all)	690	659	
Urinary tract infection			
subjects affected / exposed	400 / 5992 (6.68%)	440 / 5995 (7.34%)	
occurrences (all)	575	593	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 August 2015	Amendment 01: The secondary objective related to glycemic control was reclassified. The exploratory objective was added. Instructions that the first dose should be taken at Visit 2. Inclusion and exclusion criteria's were updated. Renal impairment: defined with reference to estimated glomerular filtration rate rather than clearance. Cyproheptadine, amoxapine, tricyclic antidepressants, and mirtazapine was deleted from the list of drugs increasing the risk for cardiac valvulopathy/PH. List of prohibited drugs was revised and the restrictions on serotonergic drugs was clarified. An analysis of subjects having worsened valvulopathy at 1 year and yearly and had FDA-defined valvulopathy at Baseline was added as a secondary endpoint. Study population for conversion to diabetes was changed to prediabetes population. Confirmatory test was needed for subjects with new onset of diabetes. Dosing instructions was modified. It was clarified that nicotine use was not exclusionary. Hospitalizations for administration of study drug or insertion of access for administration of study drug was removed from the list of hospitalization that are not SAEs because it was not applicable to the study. Clarification on subjects who permanently discontinued study drug were to complete the EOT visit within 30 days. Euphoria and suicidal ideation was moved from study-specific AEs of interest to 'SAEs and Events Associated with Special Situations'. It was added that renal function parameters and glycemic profile should be collected at all visits. It was specified that SAE collection for 30 days after the last drug dose applied only to subjects taking study drug at the time of study completion, since some subjects may have discontinued study drug before study completion. Revised footnote b in Schedule of Procedures/Assessments pertaining to unscheduled visits for assessments required by state-controlled substance requirements.
30 March 2017	Amendment 02: The primary objective of conversion to T2DM was changed to a secondary objective because the timelines to demonstrate the primary endpoint for conversion to Type 2 diabetes were not as initially projected, due to the low rate of conversion, Removed HbA1c from the exploratory objective in order to have a broader assessment of glycemic benefit in subjects with diabetes, Added FPG, fasting insulin levels, and homeostatic model assessment-insulin resistance (HOMA-IR) to better assess lorcaserin glycemic benefit, Multiple testing procedure was updated to reflect the change in the primary objective, The renal objective for the overall population was added and reorganized for clarification, Details of the interim analysis was outlined in the Study Integrity Charter, Removed the clarification of major adverse cardiovascular events (MACE)+ events accruing after 11 months after 460 MACE events have occurred, Updated the timing of the interim analysis date.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported